Pakistan recalls altered dose of Avastin; FDA rejects Botanix gel
Plus, MC2’s new licensing deal with Regranion and AM-Pharma announces a new CEO and workforce cuts.
Pakistan recalls altered Avastin
Pakistan is pulling a dose of Avastin from the market due to incidents of damaged vision in diabetic patients who received off-label “altered” or “diluted” versions of the injection. The Drug Regulatory Authority of Pakistan cited Genius Advanced Pharmaceutical Services, saying the issues are likely due to illegal sales of the drug under non-sterile conditions. Roche’s Avastin is approved to treat colorectal and metastatic carcinomas in Pakistan. It’s not authorized for use in diabetic patients or for other ophthalmic conditions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.